Viveon Health Acquisition (VHAQ) Competitors $10.00 0.00 (0.00%) (As of 12/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsOwnershipSEC FilingsTrends VHAQ vs. CMRX, ATYR, MRSN, HRTX, FULC, ACB, FATE, DMAC, LXEO, and ZNTLShould you be buying Viveon Health Acquisition stock or one of its competitors? The main competitors of Viveon Health Acquisition include Chimerix (CMRX), Atyr PHARMA (ATYR), Mersana Therapeutics (MRSN), Heron Therapeutics (HRTX), Fulcrum Therapeutics (FULC), Aurora Cannabis (ACB), Fate Therapeutics (FATE), DiaMedica Therapeutics (DMAC), Lexeo Therapeutics (LXEO), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical products" industry. Viveon Health Acquisition vs. Chimerix Atyr PHARMA Mersana Therapeutics Heron Therapeutics Fulcrum Therapeutics Aurora Cannabis Fate Therapeutics DiaMedica Therapeutics Lexeo Therapeutics Zentalis Pharmaceuticals Chimerix (NASDAQ:CMRX) and Viveon Health Acquisition (NYSE:VHAQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership. Do insiders and institutionals hold more shares of CMRX or VHAQ? 45.4% of Chimerix shares are held by institutional investors. Comparatively, 22.1% of Viveon Health Acquisition shares are held by institutional investors. 13.1% of Chimerix shares are held by company insiders. Comparatively, 75.3% of Viveon Health Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor CMRX or VHAQ? Chimerix received 393 more outperform votes than Viveon Health Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformChimerixOutperform Votes39363.80% Underperform Votes22336.20% Viveon Health AcquisitionN/AN/A Is CMRX or VHAQ more profitable? Viveon Health Acquisition's return on equity of 0.00% beat Chimerix's return on equity.Company Net Margins Return on Equity Return on Assets ChimerixN/A -50.78% -44.94% Viveon Health Acquisition N/A N/A N/A Which has stronger valuation & earnings, CMRX or VHAQ? Viveon Health Acquisition has lower revenue, but higher earnings than Chimerix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChimerix$159K1,691.25-$82.10M-$0.94-3.18Viveon Health AcquisitionN/AN/A-$610KN/AN/A Does the media refer more to CMRX or VHAQ? In the previous week, Chimerix had 5 more articles in the media than Viveon Health Acquisition. MarketBeat recorded 5 mentions for Chimerix and 0 mentions for Viveon Health Acquisition. Chimerix's average media sentiment score of 0.12 beat Viveon Health Acquisition's score of 0.00 indicating that Chimerix is being referred to more favorably in the media. Company Overall Sentiment Chimerix Neutral Viveon Health Acquisition Neutral Which has more risk and volatility, CMRX or VHAQ? Chimerix has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Viveon Health Acquisition has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Do analysts prefer CMRX or VHAQ? Chimerix presently has a consensus price target of $8.50, suggesting a potential upside of 184.28%. Given Chimerix's stronger consensus rating and higher probable upside, equities analysts clearly believe Chimerix is more favorable than Viveon Health Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chimerix 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Viveon Health Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryChimerix beats Viveon Health Acquisition on 9 of the 13 factors compared between the two stocks. Ad Porter & CompanyAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.I urge you to watch it now. Get Viveon Health Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for VHAQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VHAQ vs. The Competition Export to ExcelMetricViveon Health AcquisitionPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$66.49M$6.57B$5.14B$19.19BDividend YieldN/A2.98%5.09%3.61%P/E RatioN/A10.5089.8241.30Price / SalesN/A195.801,116.2117.58Price / CashN/A57.1642.8921.28Price / Book-3.115.094.785.32Net Income-$610,000.00$151.83M$120.23M$989.88M7 Day PerformanceN/A-2.13%-1.92%-3.54%1 Month PerformanceN/A-3.10%11.49%-3.68%1 Year Performance-11.50%11.54%30.57%12.14% Viveon Health Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$66.49MN/A0.002CMRXChimerix4.3425 of 5 stars$2.91-1.4%$8.50+192.1%+218.1%$261.73M$320,000.00-3.1472ATYRAtyr PHARMA2.4771 of 5 stars$3.10+1.3%$19.25+521.0%N/A$260.22M$235,000.00-3.2656News CoverageMRSNMersana Therapeutics4.3105 of 5 stars$2.10-2.3%$6.00+185.7%-16.2%$259.41M$36.85M-3.52150Positive NewsHRTXHeron Therapeutics3.9582 of 5 stars$1.68+4.7%$5.67+238.3%-2.5%$254.76M$137.74M-8.89300Analyst DowngradeFULCFulcrum Therapeutics1.7135 of 5 stars$4.41+11.4%$9.33+111.6%-22.6%$237.87M$80.87M-13.68100ACBAurora Cannabis0.0886 of 5 stars$4.29-0.5%N/A-8.4%$235.26M$200.35M-5.671,073Analyst RevisionNews CoverageFATEFate Therapeutics3.5326 of 5 stars$2.05+11.7%$6.75+230.1%-45.1%$232.91M$13.45M-1.22550DMACDiaMedica Therapeutics0.8119 of 5 stars$5.43+0.9%$7.00+28.9%+141.0%$232.19MN/A-9.6120News CoverageGap DownLXEOLexeo Therapeutics2.7842 of 5 stars$7.00+1.7%$23.80+240.0%-54.8%$231.46M$650,000.00-2.1858News CoverageGap DownZNTLZentalis Pharmaceuticals1.9987 of 5 stars$3.23+4.5%$10.00+209.6%-77.9%$230.17MN/A-1.24160 Related Companies and Tools Related Companies Chimerix Alternatives Atyr PHARMA Alternatives Mersana Therapeutics Alternatives Heron Therapeutics Alternatives Fulcrum Therapeutics Alternatives Aurora Cannabis Alternatives Fate Therapeutics Alternatives DiaMedica Therapeutics Alternatives Lexeo Therapeutics Alternatives Zentalis Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:VHAQ) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viveon Health Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viveon Health Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
